Board Meeting
Accretion Nutraveda Board Meeting Scheduled
Accretion Nutraveda will hold a Board meeting on 31 October 2026 to consider and approve unaudited financial results for the half year ended 30 September 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
4
Neutral
6
Bullish
4
Bearish
26
Neutral
14
Bullish
6
Bearish
22
Neutral
8
Bullish
2
Pharmaceuticals & Biotechnology
Pharmaceuticals
198 Cr
Low Risk
39.4
34.8
—
5.6
313.00
150.10
Sales CAGR
Profit CAGR
ROE
ROCE
Accretion Nutraveda Ltd (ANL) is currently trading at 273.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Accretion Nutraveda Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Accretion Nutraveda Ltd has traded between a low of ₹150.10 and a high of ₹313.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Accretion Nutraveda Ltd has a market capitalization of approximately 197.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Accretion Nutraveda Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 197.83 Cr, Accretion Nutraveda Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Accretion Nutraveda Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Accretion Nutraveda Ltd is 39.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.